Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech hopes to advance three late-stage compounds and others into development, but the overall tally will be reduced for the foreseeable future.
You may also be interested in...
As Exelixis Reigns In Spending, It Looks To Offload Early-Stage Assets
Management elaborates on plans to scale down early discovery and drug development to focus resources on its three lead partnered drugs.
As Exelixis Reigns In Spending, It Looks To Offload Early-Stage Assets
Management elaborates on plans to scale down early discovery and drug development to focus resources on its three lead partnered drugs.
Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal
Exelixis re-partners with long-term collaborator BMS the same late-stage XL184 that GSK rejected less than two months earlier.